Nurtec (rimegepant), an oral CGRP receptor antagonist, has shown potential in alleviating Visual Snow Syndrome symptoms by modulating neurovascular inflammation and reducing cortical hyperexcitability. Its mechanism involves blocking calcitonin gene-related peptide (CGRP) receptors, which may help modulate neuronal hyperactivity and potentially reduce visual disturbances associated with the syndrome.